Prothena

Historical price data

Prothena Corporation plc is a Nasdaq-listed biotech firm focused on discovering and developing transformative antibody therapies for diseases driven by protein misfolding, including Parkinson's disease and ATTR amyloidosis. The company's strategy is built upon a foundational scientific legacy from Athena Neurosciences and Elan, which has yielded key discoveries in amyloid biology and led to commercial products like Tysabri. Prothena advances a mix of wholly-owned and partnered clinical-stage assets, targeting high-need neurological and rare disease markets with significant unmet medical need. Its core competency lies in designing antibodies that selectively target pathogenic forms of proteins to modify disease progression.

Platform for rational design of antibodies that selectively target misfolded, pathogenic forms of proteins (e.g., alpha-synuclein, tau, transthyretin, amyloid-beta) while sparing normal functional proteins, leveraging deep expertise in protein dysregulation biology.

Faces direct competition in Parkinson's from other alpha-synuclein-targeting antibodies (e.g., Biogen, UCB). In ATTR amyloidosis, competes with established TTR stabilizers and RNAi therapeutics. In Alzheimer's, enters a crowded tau antibody field and an Aβ market now defined by approved therapies. Prothena's differentiation lies in its specific antibody engineering and deep protein misfolding expertise.